NASDAQ:NYXH Nyxoah (NYXH) Stock Price, News & Analysis → Urgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It! (From American Alternative) (Ad) Free NYXH Stock Alerts $10.70 +0.22 (+2.10%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$10.11▼$10.7050-Day Range$8.90▼$19.5052-Week Range$4.00▼$20.00Volume17,967 shsAverage Volume56,139 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice Target$20.60 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get Nyxoah alerts: Email Address Nyxoah MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside92.5% Upside$20.60 Price TargetShort InterestHealthy2.78% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.65 out of 5 stars 4.4 Analyst's Opinion Consensus RatingNyxoah has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageNyxoah has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 4.0 Short Interest Percentage of Shares Shorted2.78% of the float of Nyxoah has been sold short.Short Interest Ratio / Days to CoverNyxoah has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in Nyxoah has recently decreased by 11.38%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldNyxoah does not currently pay a dividend.Dividend GrowthNyxoah does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NYXH. Previous Next 0.6 News and Social Media Coverage Search Interest4 people have searched for NYXH on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Nyxoah to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next N/A Company Ownership Insider Buying vs. Insider SellingIn the past three months, Nyxoah insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Nyxoah are expected to remain at ($1.78) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nyxoah is -6.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nyxoah is -6.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNyxoah has a P/B Ratio of 2.11. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchHow to camouflage a factory of 53,000 workers"If I Had To Pour Every Single Penny of My Retirement Into Just ONE STOCK..." The former Goldman Sachs VP – who called everything from Microsoft's 1,100% surge... to the death of the 60/40 portfolio – is now stepping forward with his most explicit message yet: "Make this ONE STOCK the cornerstone of your portfolio."Get the full story here. About Nyxoah Stock (NASDAQ:NYXH)Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.Read More NYXH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NYXH Stock News HeadlinesApril 11, 2024 | markets.businessinsider.comNyxoah Appoints Maurits Boon As Chief Medical OfficerApril 11, 2024 | globenewswire.comNyxoah Appoints Dr. Maurits S. Boon, MD as Chief Medical OfficerApril 25, 2024 | Stansberry Research (Ad)How to camouflage a factory of 53,000 workers"If I Had To Pour Every Single Penny of My Retirement Into Just ONE STOCK..." The former Goldman Sachs VP – who called everything from Microsoft's 1,100% surge... to the death of the 60/40 portfolio – is now stepping forward with his most explicit message yet: "Make this ONE STOCK the cornerstone of your portfolio."April 11, 2024 | benzinga.comWhy Rallybio Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving PremarketMarch 29, 2024 | finance.yahoo.comInformation on the total number of voting rights and sharesMarch 26, 2024 | markets.businessinsider.comBuy Rating Affirmed for Nyxoah’s Genio System Amid Strategic Partnerships and Market Capture PotentialMarch 25, 2024 | globenewswire.comNyxoah Advances Patient Access Strategy through Partnership with the American Association of Otolaryngology – Head & Neck Surgery FoundationMarch 20, 2024 | markets.businessinsider.comBuy Rating Affirmed for Nyxoah Amid Promising DREAM Study Results and Market Growth ProjectionsApril 25, 2024 | Stansberry Research (Ad)How to camouflage a factory of 53,000 workers"If I Had To Pour Every Single Penny of My Retirement Into Just ONE STOCK..." The former Goldman Sachs VP – who called everything from Microsoft's 1,100% surge... to the death of the 60/40 portfolio – is now stepping forward with his most explicit message yet: "Make this ONE STOCK the cornerstone of your portfolio."March 19, 2024 | msn.comNyxoah says Genio pivotal study meets primary endpointsMarch 19, 2024 | globenewswire.comNyxoah Announces DREAM U.S. Pivotal Study Meets Primary EndpointsMarch 7, 2024 | seekingalpha.comNyxoah S.A. (NYXH) Q4 2023 Earnings Call TranscriptMarch 7, 2024 | finance.yahoo.comNyxoah S.A. (NASDAQ:NYXH) Q4 2023 Earnings Call TranscriptMarch 6, 2024 | markets.businessinsider.comBuy Rating Affirmed for Nyxoah Amid Record Genio Sales and Strong Growth ProspectsMarch 5, 2024 | investorplace.comNYXH Stock Earnings: Nyxoah Misses EPS, Beats Revenue for Q4 2023March 5, 2024 | globenewswire.comNyxoah Reports Fourth Quarter and Financial Year 2023 Financial and Operating ResultsMarch 4, 2024 | benzinga.comPreview: Nyxoah's EarningsFebruary 29, 2024 | globenewswire.comNyxoah to Participate in the Oppenheimer 34th Annual Healthcare MedTech & Services ConferenceFebruary 26, 2024 | msn.comButterfly Network, ThermoGenesis among healthcare moversFebruary 15, 2024 | finance.yahoo.comNyxoah to Release Fourth Quarter and Financial Year 2023 Financial Results on March 5, 2024February 15, 2024 | globenewswire.comNyxoah to Release Fourth Quarter and Financial Year 2023 Financial Results on March 5, 2024February 9, 2024 | morningstar.comNyxoah SA Ordinary Shares NYXHJanuary 17, 2024 | finance.yahoo.comNyxoah Announces 2024 Strategic PrioritiesJanuary 10, 2024 | msn.comNyxoah expects to almost double revenue in 4Q23January 9, 2024 | finance.yahoo.comNyxoah Announces Preliminary Results for the Fourth Quarter and Full Year 2023December 12, 2023 | markets.businessinsider.comBuy Rating on Nyxoah’s Genio System Amid Strong Market Potential and Positive Clinical DataDecember 11, 2023 | finance.yahoo.comNyxoah Announces Real World Case Series Demonstrating Positive Results in Treating CCC Patients with Genio®See More Headlines Receive NYXH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nyxoah and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/05/2024Today4/24/2024Next Earnings (Estimated)5/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:NYXH CUSIPN/A CIK1857190 Webwww.nyxoah.com Phone321-022-2355Fax321-045-9075Employees137Year FoundedN/APrice Target and Rating Average Stock Price Target$20.60 High Stock Price Target$27.00 Low Stock Price Target$14.00 Potential Upside/Downside+92.5%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.68) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-46,770,000.00 Net Margins-993.28% Pretax Margin-1,027.03% Return on Equity-38.58% Return on Assets-31.24% Debt Debt-to-Equity Ratio0.12 Current Ratio4.73 Quick Ratio4.50 Sales & Book Value Annual Sales$4.70 million Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.08 per share Price / Book2.11Miscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta1.50 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Robert Taub MBA (Age 77)Co-Founder & Chairman Comp: $138.25kMr. Olivier Taelman (Age 52)CEO & Executive Director Comp: $683.69kMr. Loic Moreau (Age 43)Chief Financial Officer Comp: $343.41kMr. Bruno OnkelinxChief Technology OfficerMikaela KirkwoodCorporate Communication & Investor Relations ManagerMs. An MoonenGeneral CounselMr. Remi RenardVice President of Market & Market AccessMs. Inge VanwittenberghGlobal Human Resource DirectorMr. David M. DeMartinoChief Strategy OfficerMr. Jeyakumar SubbaroyanChief Clinical OfficerMore ExecutivesKey CompetitorsStevanato GroupNYSE:STVN180 Life SciencesNASDAQ:ATNFW60 Degrees PharmaceuticalsNASDAQ:SXTPWAclarionNASDAQ:ACONWAinosNASDAQ:AIMDWView All CompetitorsInstitutional OwnershipOpaleye Management Inc.Sold 97,096 shares on 2/15/2024Ownership: 1.383%View All Institutional Transactions NYXH Stock Analysis - Frequently Asked Questions Should I buy or sell Nyxoah stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nyxoah in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" NYXH shares. View NYXH analyst ratings or view top-rated stocks. What is Nyxoah's stock price target for 2024? 6 brokerages have issued 1-year price targets for Nyxoah's stock. Their NYXH share price targets range from $14.00 to $27.00. On average, they expect the company's stock price to reach $20.60 in the next twelve months. This suggests a possible upside of 92.5% from the stock's current price. View analysts price targets for NYXH or view top-rated stocks among Wall Street analysts. How have NYXH shares performed in 2024? Nyxoah's stock was trading at $4.64 on January 1st, 2024. Since then, NYXH stock has increased by 130.6% and is now trading at $10.70. View the best growth stocks for 2024 here. When is Nyxoah's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 21st 2024. View our NYXH earnings forecast. How were Nyxoah's earnings last quarter? Nyxoah S.A. (NASDAQ:NYXH) issued its quarterly earnings data on Tuesday, March, 5th. The company reported ($0.41) EPS for the quarter, hitting analysts' consensus estimates of ($0.41). The company earned $1.96 million during the quarter, compared to analyst estimates of $2.01 million. Nyxoah had a negative net margin of 993.28% and a negative trailing twelve-month return on equity of 38.58%. When did Nyxoah IPO? Nyxoah (NYXH) raised $83 million in an initial public offering on Friday, July 2nd 2021. The company issued 2,760,000 shares at $30.00 per share. How do I buy shares of Nyxoah? Shares of NYXH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NYXH) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsFed launches fourth dollar overhaulStansberry ResearchGreat Crypto BullWeiss RatingsMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nyxoah S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
